Magnolol

T47D and CAMA‐1 cell lines were purchased from DSMZ (Brunswick, Germany) and ATCC (Manassas, VA, USA), respectively. After reconstitution, all cells were passaged for a maximum of 2–3 months and regularly tested for mycoplasma contamination. T47D cells were grown in DMEM (Corning, NY, USA) and CAMA‐1 cells in MEM (Corning), both supplemented with 10% FBS (Biowest, Nuaillé, France), 100 U·mL⁻¹ penicillin and 100 μg·mL⁻¹ streptomycin (HyClone, Logan, UT, USA). For all treatments, the standard media were replaced with phenol red‐free DMEM (HyClone), serum‐free or, when appropriate, supplemented with 10% charcoal‐stripped FBS (Biowest). FGF7 (50 ng·mL⁻¹, PeproTech, Rocky Hill, NJ, USA) was always applied with heparin sodium salt (50 ng·mL⁻¹; Sigma‐Aldrich, St. Louis, MO, USA). 17β‐oestradiol (E2, oestrogen, 10 nm), progesterone (P4, 100 nm), 4‐hydroxytamoxifen (OHT, 1 μm), LY294002 (2 μm), SP600125 (10 μm), SU6656 (10 μm), UO126 (10 μm), and LiCl (20 mm) were purchased from Sigma‐Aldrich, AZD4547 (0.5 μm), SB216763 (10 μm), ABT‐199 (5 μm), SB202190 (10 μm) and Magnolol (10 μm) from Selleckchem (Houston, TX, USA) and BI‐D1870 (1 μm) from Axon Medchem (Groningen, the Netherlands).

The 3-glycidoxypropyltrimethoxysilan (GOPTS) was from Sinopharm Chemical Regent Company (Shanghai, China). Bovine serum albumin (BSA) and phosphate buffered saline (PBS) were from Sigma-Aldrich (St. Louis, MO, USA). Streptavidin (SA) was from Life Technologies (Shanghai, China). Biotin was from Aladdin Industrial Corporation (Shanghai, China). Magnolol, medetomidine HCl, cetrimonium bromide, and reboxetine mesylat were from Selleck (Houston, TX, USA). The low refractive index polymer MY133 was from MY Polymers (Ness Ziona, Israel). The UV glue was from Thorlabs (Shanghai, China).